New Leaf Venture Partners is a leading healthcare technology focused venture capital firm with a team of senior partners that has been successfully investing together for nearly 2 decades. The New Leaf team has invested over $1.7 billion in 126 healthcare technology companies within 6 distinct funds since 1995. NLV focuses on investments in the biopharmaceutical, information convergence (HCIT), medical device, and biological research tools & infrastructure sectors. Our goal is to generate outstanding returns for our limited partners by building strong companies that are developing clinically important and commercially attractive products.

Across all sectors and stages, the New Leaf team is focused on building value in companies by creating strong management teams and then collaborating with them to develop, manage, and execute capital efficient business plans. Investment decisions are primarily driven by a fundamental assessment of the risks in the underlying development programs (i.e., technical, clinical, regulatory, financial, and commercial risks). Through these efforts, New Leaf has earned a reputation as a value-added investor and has created consistently top-performing portfolios of healthcare technology investments.

The NLV investment team has deep operating experience and medical and technical expertise as well as broad networks of noteworthy advisors and consultants across academia, industry, and clinical medicine which are integral to our active investment approach. This allows us to work closely with founders, management, and co-investors on identifying and achieving optimal paths to value creation and exit.

NLV Partners has offices in New York and San Mateo, California. We are currently investing through our various funds.

VaxInnate Receives Extension of Contract from BARDA for Development of Seasonal and Pandemic Influenza Vaccines

Oxford Immunotec Global PLC Announces Pricing of Underwritten Offering of Ordinary Shares

Versartis Announces Pricing of Follow-On Offering

Biogen Idec to Expand Neuropathic Pain Portfolio with the Acquisition of Convergence Pharmaceuticals

Chimerix Receives Notice of Allowance for Brincidofovir Composition of Matter Patent Extending Exclusivity to 2034